tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lower Urinary Tract Symptoms
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Trial Timeline
Apr 26, 2010 → Dec 14, 2011
NCT ID
NCT01021332About tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg) is a phase 3 stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT01021332. Target conditions include Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia.
What happened to similar drugs?
5 of 13 similar drugs in Lower Urinary Tract Symptoms were approved
Approved (5) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01021332 | Phase 3 | Completed |
Competing Products
20 competing products in Lower Urinary Tract Symptoms